glp-1 news nov 2025 What's next for innovation: A primer on the race reshaping pharma and chronic disease care November in review: GLP-1 breakthroughs,

There is no physiological reason you cannot alternate between protocols

These agents act more specifically, which lowers side effects and improves patient outcomes

Molecule of the Month: GLP-1 Receptor Agonists Popular and effective drugs for the treatment of obesity and diabetes Improving on a lizard toxin Small molecule mimics Exploring the Structure Compare how peptide-based and small molecule drugs bind to the GLP-1 receptor While peptide-based GLP-1 receptor agonists all bind to the GLP-1 receptor in similar ways, the small molecule orforglipron is much smaller with far fewer interactions

We found that administering 80-nM GLP-1 significantly counteracted the inhibitory effect of pasireotide on high glucose (20 mM)-induced insulin production, aligning with the cAMP levels in GLP-1R-MIN-6 cells

Int J Mol Med 2017;39:102936.ArticlePubMed 57

You can join the waitlist for Retatrutide and complete the consultation form on our website